Purine NR2B Modulators With Brain Penetration and Low Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing NR2B negative allosteric modulators exhibit drawbacks in receptor pharmacology and drug properties, limiting their potential use in human therapy, and non-selective NMDA receptor antagonists like ketamine have undesirable side effects.
Innovation Solution
Development of novel purine derivatives with specific structural substitutions that act as potent NR2B negative allosteric modulators, demonstrating favorable brain penetration, low efflux, and metabolic stability, thereby minimizing side effects and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective NMDA receptor antagonists like ketamine are used, then rapid antidepressant efficacy is achieved, but dissociative and psychogenic side effects occur
Solution Approach 1:
The patent applies local quality by designing compounds with selective affinity for the NR2B subunit of the NMDA receptor. The purine derivative structure with specific substituents (R1, R2, R3, R4, R5, R6, R7, R8) creates localized molecular features that preferentially bind to NR2B-containing receptors rather than all NMDA receptors, thereby achieving antidepressant effects while minimizing side effects associated with non-selective antagonism.
Solution Approach 2:
The invention segments the NMDA receptor target into specific subunit types (NR2B vs. other subunits). By developing compounds that specifically modulate NR2B-containing receptors, the patent divides the broad NMDA receptor population into selective targets, allowing differential modulation that preserves therapeutic benefits while reducing adverse effects from off-target activity.
2Adaptability or versatility
If existing NR2B negative allosteric modulators are developed, then selectivity is improved, but drawbacks in receptor pharmacology and drug properties limit therapeutic use
Solution Approach 1:
The patent employs parameter changes by systematically varying the chemical structure of purine derivatives through different substituent combinations (R1-R8 groups including phenyl, pyridyl, pyrimidinyl, and their substituted variants). This structural parameter optimization adjusts both the selectivity for NR2B receptors and the pharmacokinetic properties (metabolic stability, brain penetration, efflux characteristics) to achieve compounds suitable for human therapy.
3Reliability
If purine derivatives with specific substitutions are designed, then brain penetration and metabolic stability are improved, but structural complexity increases
Solution Approach 1:
The invention uses composite material principles by combining the purine core structure with various aromatic substituent groups (phenyl, pyridyl, pyrimidinyl) and functional moieties. This composite molecular architecture integrates multiple structural elements that collectively provide the desired pharmacokinetic properties (brain penetration, metabolic stability) while maintaining manageable synthesis routes through modular assembly of well-characterized chemical building blocks.
Data Source
AI summary
The present invention relates to novel purines of general formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.